Halozyme Therapeutics, Inc.
HALO Real Time Price USDRecent trades of HALO by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in HALO holdings by institutional investors
Quarterly net insider trading by HALO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$80,000 Jul 20, 2026 Issue: Medicare/Medicaid Health Issues
-
$70,000 Apr 18, 2026 Issue: Health Issues Medicare/Medicaid
-
$60,000 Jan 18, 2026 Issue: Health Issues Medicare/Medicaid
-
$60,000 Oct 18, 2025 Issue: Health Issues Medicare/Medicaid
-
$60,000 Jul 18, 2025 Issue: Health Issues
-
$60,000 Apr 15, 2025 Issue: Health Issues
-
$60,000 Jan 17, 2025 Issue: Health Issues
-
$60,000 Oct 17, 2024 Issue: Health Issues
-
$60,000 Jul 12, 2024 Issue: Health Issues
-
$60,000 Oct 17, 2023 Issue: Medicare/Medicaid
-
$20,000 Jul 16, 2023 Issue: Medicare/Medicaid
-
$30,000 Apr 19, 2020 Issue: Science/Technology Health Issues Medicare/Medicaid
-
$30,000 Jan 19, 2020 Issue: Medicare/Medicaid Science/Technology Health Issues
-
$20,000 Oct 20, 2019 Issue: Medicare/Medicaid Science/Technology Health Issues
-
$20,000 Aug 08, 2006 Issue: Health Issues Pharmacy
-
$20,000 Feb 14, 2006 Issue: Health Issues Pharmacy
Former government officials who have lobbied for HALO
7 former government officials from 6 congressional offices at 1 lobbying firm have lobbied for HALO, most recently Jul 16, 2023.
-
Barrett Thornhill Senate New Legislative Assistant, Sen. Mike Crapo (2003-2006); Legislative Assistant, Rep. Pat Toomey (2002-2003) -
Michael Williams House New Legislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Doug Jones (2019); Legislative Correspondent, Sen. Doug Jones (2018-2019) -
Elizabeth Greer House New Chief of Staff, Rep. Allen Boyd, Jun. 2001 - Feb. 2009 -
Jeffrey Forbes Senate New Staff Director, Senate Finance Committee, 2003 - 2003; Chief of Staff, Senator Max Baucus, 1999 - 2002; Deputy Director EOP, 1998 - 1999 -
Jeffrey Strunk House New Deputy Floor Director, House Speaker Boehner, Dec. 2010 - Jan. 2013; Floor Assistant, House Speaker Boehner, Sep. 2007 - Dec. 2010; Legislative Assistant, John Boehner, Apr. 2006 - Dec. 2010; Staff Member, Pat Tiberi, Nov. 2004 - Apr. 2006 -
Derrick White Senate New Deputy Communications Director, Senator Orrin Hatch, 2000 - 2001 -
Kristina Dunklin House New Legislative Director, Rep. Brooks, 2018 - 2019; Legislative Director, Rep. Valadao, 2015-2018; Legislative Assistant, Rep. Valadao, 2014-2015
HALO Estimated quarterly lobbying spending
HALO Revenue by Segment or Geography
New HALO patent grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded to HALO from public contracts
Recent insights relating to HALO
Recent picks made for HALO stock on CNBC
ETFs with the largest estimated holdings in HALO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $HALO stock a Buy, Sell, or Hold?
- What is the price target for $HALO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $HALO stock?
- Who owns the most shares of $HALO stock?
- What funds own $HALO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view HALO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Address San Diego, CA
- Market Cap 12.9 billion
- Employees 423
- Industrial Classification Biological Products, (No Diagnostic Substances)
Halozyme Therapeutics, Inc. (HALO) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Halozyme Therapeutics, Inc. (HALO).
Quiver Premium charts HALO's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at HALO, per a recent SEC DEF 14A filing. We estimate that the median employee at HALOZYME THERAPEUTICS, INC. is paid $220,881.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|